Securian Asset Management Inc. Reduces Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Securian Asset Management Inc. trimmed its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.9% during the second quarter, HoldingsChannel reports. The institutional investor owned 10,240 shares of the medical equipment provider’s stock after selling 200 shares during the period. Securian Asset Management Inc.’s holdings in Zimmer Biomet were worth $934,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Washington Trust Advisors Inc. purchased a new position in shares of Zimmer Biomet in the 1st quarter valued at $30,000. Columbia River Financial Group LLC purchased a new position in shares of Zimmer Biomet in the 1st quarter valued at $30,000. Accent Capital Management LLC purchased a new position in shares of Zimmer Biomet in the 1st quarter valued at $35,000. Cullen Frost Bankers Inc. grew its position in shares of Zimmer Biomet by 1,452.4% in the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 305 shares during the last quarter. Finally, Zions Bancorporation National Association UT purchased a new position in shares of Zimmer Biomet in the 1st quarter valued at $48,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $103.13 on Friday. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The business’s 50 day moving average is $101.86 and its two-hundred day moving average is $97.71. The stock has a market capitalization of $20.43 billion, a price-to-earnings ratio of 25.09, a PEG ratio of 2.39 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same period in the previous year, the business earned $2.01 earnings per share. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet’s payout ratio is 23.36%.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.39% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Royal Bank Of Canada set a $111.00 price objective on shares of Zimmer Biomet in a research report on Friday, October 10th. UBS Group raised their price objective on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a research report on Friday, August 8th. Stifel Nicolaus raised their price objective on shares of Zimmer Biomet from $115.00 to $118.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Redburn Partners set a $130.00 price objective on shares of Zimmer Biomet in a research report on Thursday, September 18th. Finally, Evercore ISI lowered their price objective on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 7th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average price target of $111.94.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.